CORDIS - EU research results

Mycobacteriophages to treat tuberculosis - Passed station or future promise?

Project description

Bacteriophages in the treatment of tuberculosis

Bacteriophages are viruses that infect and kill bacteria. The growing threat of drug resistance brought back interest in this treatment option. Funded by the Marie Skłodowska-Curie Actions programme, the Phage-TB project aims to develop clinical mycobacteriophage (MBP) treatments for tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections. The DNA of soil-isolated MBPs will be sequenced to select promising MBPs with lytic effects against TB or NTM infections. The phage cocktails will be optimised for inhalation method in the clinical treatment, preserving the phages intact and functional. The selected MBP cocktail against TB will be used in the first clinical study in humans to assess safety, dosing and efficacy.


The emergence of drug-resistance to tuberculosis (TB) drugs poses an increasing challenge to TB control and new treatment options are urgently needed. Novel or repurposed antibiotics are still being introduced, but this pipeline will dry out in the near future.
Bacteriophages are viruses that kill bacteria. They have been used to treat infections before the introduction of antibiotics. With the emergence of drug-resistance there is renewed interest in this ancient treatment option. Clinical use of mycobacteriophages to treat TB and non-tuberculous mycobacterial (NTM) infections is still in its infancy.
This project contributes to 3 areas in the development of clinically useful mycobacteriophage treatments for TB and NTM infections:
- Phage discovery: From soil samples collected in the compounds of TB clinics and hospitals in Cape Town, South Africa, we will isolate mycobacteriophages using spot tests and plaque assays. DNA of newly discovered mycobacteriophages will be sequenced and during the return phase of this project I will select promising mycobacteriophages with lytic effect against TB or NTM infections, that can be used for development of phage cocktails for clinical use.
- Phage inhalation method: the efficiency of phage treatment is dependent upon the phage concentration reached at the site of disease. Phages that can attack M tuberculosis have long tails which might be vulnerable to manipulation. We will optimize an inhalation method leaving the phages intact and functional.
- Preparation for a clinical trial: an existing mycobacteriophage cocktail active against TB will be used for a first clinical study in humans to assess dosing, safety and efficiency.
If our mycobacteriophage hunt is successful, and the translation can be made into purified and adequately dosed administration of mycobacteriophages, a virtually inexhaustible addition will be made to the therapeutic armamentarium for drug-resistant as well as drug-sensitive TB and NTM infections.


Net EU contribution
€ 238 993,92
6525 GA Nijmegen

See on map

Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Total cost
No data

Partners (2)